Novel benzylimidazole derivatives of the formula: ##STR1## wherein X is halogen, nitro, alkyl, alkoxy, or halobenzyloxy;

m is an integer of 0 to 3;

Y is oxa, thia or substituted- or unsubstituted-imino;

R1 is alkyl, dialkylaminoalkyl, dibenzylaminoalkyl, 1-pyrrolidinyl, 2-imidazolin-2-yl, or a group of --(CH2)n--Z--Q

(wherein

n is an integer of 0 to 4;

Z is oxa, thia, or a single bond; and

Q is substituted- or unsubstituted-phenyl or thienyl) ##STR2## is methylene, 1-(1-imidazolyl)-1-methylmethylene, 1-(1-imidazolyl)-1-phenylmethylene, 1-phenylmethylene, or substituted or unsubstituted alkylidene;

the benzene ring of the above formula being optionally condensed with another benzene ring

with the proviso that when ##STR3## is methylene said benzene ring is condensed with another benzene ring, and acid addition salts thereof which are useful as an antimycotic drug or agricultural fungicide.

Patent
   4328348
Priority
Jun 07 1979
Filed
Jun 06 1980
Issued
May 04 1982
Expiry
Jun 06 2000
Assg.orig
Entity
unknown
11
4
EXPIRED
1. A compound of the formula: ##STR71## wherein X is halogen, nitro, C1 to C5 alkyl, C1 to C5 alkoxy or halobenzyloxy;
m is an integer of 0 to 3;
Y is oxa, thia or imino optionally substituted by C1 to C5 alkanoyl, C1 to C5 halo-alkanoyl or C1 to C5 alkyl;
R1 is C1 to C5 alkyl, C3 to C10 dialkylaminoalkyl, C15 to C20 dibenzylamino-alkyl, 1-pyrrolidinyl, 2-imidazolin-2-yl or a group of the formula --(CH2)n --Z--Q wherein n is an integer of 0 to 4, Z is oxa, thia or a single bond and Q is phenyl or thienyl optionally substituted by 1 to 3 members selected from the group consisting of halogen, nitro, C1 to C5 alkyl and C1 to C5 alkoxy; and
R4 is C1 to C5 alkylidene optionally substituted by phenyl,
the benzene ring in the above formula being optionally condensed with another benzene ring,
or a pharmaceutically acceptable acid addition salt thereof.
2. A compound according to claim 1, wherein R4 is CH2.
3. The compound 1-[1-(2-(3-chlorobenzyloxy)phenyl)vinyl]imidazole.
4. The compound 1-[1-(2-(4-chlorobenzyloxy)phenyl)vinyl]imidazole.
5. The compound 1-[1-(2-(phenethyloxy)phenyl)vinyl]imidazole.
6. The compound 1-[2-(4-chlorobenzyloxy)phenyl]-1,1-bis(1-imidazolyl)-1-phenylmethane.

This invention relates to novel benzylimidazole derivatives useful as an antimycotic drug or agricultural fungicide. Such compounds are, for example, disclosed in Japanese Unexamined Patent Publication No. 50-148357 and the European Journal of Medicinal Chemistry 14, No. 3, pp 227-230, 231-237, 243-245 (1979). But the compounds of the following formula (I) are novel. ##STR4## , wherein X is halogen, nitro, C1 to C5 alkyl, C1 to C5 alkoxy or halo-benzyloxy;

m is an integer of 0 to 3;

Y is oxa, thia or imino optionally substituted by C1 to C5 alkanoyl, C1 to C5 halo-alkanoyl or C1 to C5 alkyl;

R1 is C1 to C5 alkyl, C3 to C10 dialkylaminoalkyl, C15 to C20 dibenzylaminoalkyl, 1-pyrrolidinyl, 2-imidazolin-2-yl, or a group of --(CH2)n--Z--Q

(wherein

n is an integer of 0 to 4;

Z is oxa, thia, or a single bond;

Q is phenyl or thienyl optionally substituted by 1 to 3 members selected from halogen, nitro, C1 to C5 alkyl, and C1 to C5 alkoxy); ##STR5## is methylene, 1-(1-imidazolyl)-1-methylmethylene, 1-(1-imidazolyl)-1-phenylmethylene, 1-phenylmethylene, or C1 to C5 alkylidene optionally substituted by phenyl;

the benzene ring of the above formula being optionally condensed with another benzene ring

with the proviso that when ##STR6## is methylene said benzene ring is condensed with another benzene ring, and pharmaceutically acceptable acid addition salts thereof.

In the above general formula, halogen means chloro, bromo, fluoro and iodo, preferably chloro. C1 and C5 Alkyl means methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, pentyl, isopentyl, and the like and C1 to C5 alkoxy means methoxy, ethoxy, propoxy, isopropoxy, butyloxy, sec-butyloxy, pentyloxy, isopentyloxy, and the like. C1 to C5 Alkanoyl means formyl, acetyl, propionyl, butyryl, and the like. C3 to C10 Dialkylaminoalkyl means dimethylaminoethyl, diethylaminoethyl, dipropylaminobutyl, methylethylaminoethyl, and the like. C1 to C5 Alkylidene means methylene, ethylidene, propylidene, isopropylidene, butylidene, pentylidene, and the like.

Compounds (I) can be easily converted to the corresponding pharmaceutically acceptable acid addition salts, which are included within the scope of this invention. Representative acids which can form the pharmaceutically acceptable salts are organic acids such as acetic acid, citric acid, tartaric acid, methanesulfonic acid, malic acid, succinic acid, oxalic acid, salicyclic acid, or the like and inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, or the like.

Compounds (I) may be prepared according to the following scheme: ##STR7## (wherein M is hydrogen or alkali metal;

A is halogen or an ester residue;

B and D each is hydrogen or alkyl;

and X, m, Y, R1, R2 and R3 each has the same significance as given earlier)

(First Step)

This process may be carried out by reacting Compound (II) with Compound (III) in the presence of a base in an inert solvent at room temperature or under heating. Representative bases are sodium hydroxide, potassium hydroxide, sodium hydride, sodium amide, potassium amide, sodium ethoxide, potassium carbonate, and the like. Representative inert solvents are dimethylformamide, benzene, methanol, chloroform, dioxane, tetrahydrofuran, acetone, and the like.

The starting compound (II) is available, for example, by treating the ketone (IV) with N,N'-thionyldiimidazole or N,N'-carbonyldiimidazole for imidazole formation. The reaction is carried out in an inert solvent such as methylene chloride, chloroform, tetrahydrofuran, dioxane, benzene, acetonitrile, or 1,2-dichloroethane at room temperature or under cooling.

(Second Step)

The reaction of the starting compound (IV) with the compound (III) may be carried out in the same manner as in the First Step. Then the intermediate (V) is subjected to the imidazole formation in the same manner as in the above preparation of the starting compound (II).

IV. Effect

Compounds (I) and the pharmaceutically acceptable salts thereof prepared in this invention exhibit excellent antimycotic activities and are useful as an antimycotic drug for humans and animals.

Minimum Inhibitory Concentration (MIC, μ/ml) in vitro of some typical Compounds (I) are indicated in the following Table 1. The compound numbers correspond to the structure of the products prepared in the respective numbered Examples.

TABLE 1
______________________________________
MIC Values (γ/ml)
Fungi
Compound Aspergillus
Candida Trichophyton
No. fumigates albicans M-9
asteroides
______________________________________
1 3.1 6.2 <0.1
7 1.6 100.0 <0.1
8 1.6 25.0 50.0
13 1.6 6.2 <0.1
17 3.1 3.1 <0.1
22 1.6 6.2 <0.1
28 6.2 12.5 <0.1
34 6.2 50.0 1.6
39 0.4 6.2 <0.1
40 12.5 25 1.6
41 6.2 3.1 <0.1
42 3.1 12.5 3.1
43 1.6 12.5 3.1
44 3.1 12.5 3.1
45 6.2 25 3.1
46 6.2 25 3.1
47 6.2 12.5 1.6
62 0.8 25.0 <0.1
66 6.2 12.5 0.2
67 6.2 6.2 0.2
68 6.2 12.5 3.1
69 12.5 25 1.6
______________________________________

Compounds (I) and their acid addition salts exhibit excellent antifungal activities against various phytopathogenic fungi and soil borne pathogens and are useful as agricultural fungicides.

(1) Test Method

A seed of cucumber (cultivar:Matsukaze) was sown in a vinyl chloride-cup of 9 cm in diameter containing soil in a greenhouse and cultivated. At the primary leaf stage, 2.5 ml each of the solution containing a prescribed concentration of the test compound was applied over the above cucumber, which was kept at 25° to 26°C in 80% humidity for 24 hours. A suspension of Botrytis cinerea spores was inoculated onto the leaves at five spots per leaf and the leaves were kept at 80°C in 95% humidity for 72 hours.

(2) Results

The results are shown by percent disease control (%) calculated from the diseased degree according to the following formula. ##EQU1##

The compounds numbered in the following Table 2 each have the same structure as that of the compounds in the corresponding numbered Examples.

TABLE 2
______________________________________
Compd. Concentration Percent Disease
No. (ppm) Diseased Degree
Control (%)
______________________________________
1 500 0 100
3 " " "
6 " " "
7 " 40 60
8 " 0 100
15 " " "
17 " " "
24 " " "
27 " " "
34 " " "
61 " " "
62 " " "
un-
treated -- 100 0
______________________________________
(Note)-
Diseased degrees were calculated according to the subsequent
Disease condition
Marks Numbers examined
______________________________________
Largely faded lesions
formed at inoculated
20 a
parts
Back of the inoculated
leaf faded 10 b
Back of the inoculated
leaf slightly faded
5 c
No disease 0 d
______________________________________
##STR8##

(1) Test Method

A seed of cucumber (cultivar:Matsukaze) was sown on a vinyl chloride-cup of 9 cm in diameter in a greenhouse containing soil and cultivated. At the primary leaf stage, 2.5 ml each of the solution containing a prescribed concentration of the test compound was applied over the above cucumber, which was kept at 25° to 26°C in 80% humidity for 24 hours. A suspension of Colletotrichum lagenarium spores was inoculated onto the above leaves at five spots per leaf and the leaves were kept at 25°C in 95% humidity for 1 day and at 25°C in 75 to 80% humidity for 6 days.

(2) Results

Percent disease control (%) was calculated as mentioned in the above test 1.

TABLE 3
______________________________________
Compd. Concentration Percent Disease
No. (ppm) Diseased Degree
Control (%)
______________________________________
46 500 20 80
58 " 0 100
un-
treated -- 100 0
______________________________________

(1) Test Method

A seed of cucumber (cultivar:Matsukaze) was sown in a vinyl chloride-cup of 9 cm in diameter containing soil in a greenhouse and cultivated. At the primary leaf stage, 5 ml each of a solution of the test compound in a prescribed concentration was applied over the above cucumber, which was kept at 25° to 26°C for 1 day. Primary leaves of cucumber previously infected by pathogenic fungi of the powdery mildew (Shpaerotheca fuliginea) were taken and those having lesions covered with spores were cut out in 1 square centimeter pieces, which were stuck to the primary leaves in the cups for inoculation, four plots per leaf. The above treated leaves were kept at 25° to 26°C for 10 days.

The spore formation on the inoculated plots was observed by a microscope.

Standard of the evaluation:

(+): Formation of many spores and hypae observed on the inoculated plots

(-): Neither infected spots nor spore formation observed on the inoculated plots

(2) Results

______________________________________
Compd. No. Concentration (ppm)
Diseased Degree
______________________________________
5 500 -
21 " -
36 " -
78 " -
80 " -
untreated -- +
______________________________________

(1) Test Method

Seedlings of rice plant (cultivar:Aichi-asahi) reared in a greenhouse for 10 days were transplanted in a vinyl chloride-cup of 9 cm in diameter. A solution of the test compound at a prescribed concentration was applied to the above rice plants 14 days after the transplanting. One day after the application, a spore suspension of pathogenic fungi of rice plant blast (Pyricularia oryzae) was sprayed on the leaf blades of the seedlings, which were kept at 28°C in 98% humidity for 24 hours and at 28°C in 90% humidity for 7 days in a greenhouse. The number of infected spots on the inoculated leaves was observed.

(2) Results

The results are shown by percent disease control which was calculated according to the following formula:

______________________________________
Percent Disease Control (%) =
##STR9##
Compd. Concentration
Number of Percent Disease
No. (ppm) Spots Control (%)
______________________________________
23 500 271 89.5
28 " 45 98.3
36 " 25 99.0
78 " 99 96.2
un-
treated -- 2589 0
______________________________________

Compounds (I) or the salts thereof may be applied in a wide variety of oral or parenteral dosage forms solely or in admixture with additives such as diluents, carriers, dispersants and the like. The pharmaceutical compositions may be in the form of solutions, suspensions, powders, granules, tablets, injections, ointments, tinctures, and the like. The formulations may be dispensed in a conventional manner. For example, Compounds (I) may be administered at a dose of 100 to 2000 mg per day for enteral application.

Further, compounds (I) and the salts thereof exhibit an excellent control effect against the following phyto-pathogenic fungi and other soil borne pathogens.

Rice plant: blast, damping-off, leaf spot

Wheat and barley: stem rust, loose smut, powdery mildew

Pear: red spot, scab, Alternaria leaf spot

Grape: gray rust, ripe rot, downy mildew, leaf spot, white rot, gray mold, powdery mildew

Apple: Alternaria leaf spot, canker, black spot, red spot, blossom blight

Peach: brown rot

Cucumber: downy mildew, anthracnose, sclerotinia rot, gray mold, powdery mildew

Green pepper: powdery mildew

Tobacco: brown spot, powdery mildew

Compounds (I) or the salts thereof may be formed into wettable powders, granules, powders, emulsions, tablets, aerosols, fumigations, oils, and the like solely or in admixture with additives or carriers ordinarily employed in agricultural fungicides. Compounds (I) may be applied to plants at a dose of 0.5 to 100 g per are.

The following examples are provided to further illustrate this invention.

EXAMPLE 1 ##STR10## (step a)

To a solution of 60 g of imidazole in 300 ml of dry methylene chloride is added 26.2 g of thionyl chloride, and the mixture is stirred at room temperature for 10 minutes, mixed with 20 g of Compound (1), and stirred at room temperature for 1.5 hours. The reaction mixture is mixed with ice water and extracted with methylene chloride. The organic layer is washed with water, dried over Glauber's salt, and concentrated. The residue is dissolved in a mixture of 5% methanol and methylene chloride and chromatographed on a column of silica gel. The eluate is concentrated and the residue is washed with a mixture of ethyl acetate and isopropyl ether to give 25.8 g of Compound (2).

mp. 150°-151°C

IR: νmaxNujol 3300-2100, 2570, 1630 cm-1.

(step b)

To a solution of the sodium salt of Compound (2) prepared from 500 mg of Compound (2), 164 mg of 60% sodium hydride and 5 ml of dry dimethylformamide is added 828 mg of p-chlorobenzyl bromide, and the mixture is stirred at room temperature for 15 minutes. The reaction mixture is mixed with ice water and extracted with methylene chloride. The organic layer is washed with water, dried over Glauber's salt, and concentrated. The residue is chromatographed on a column of silica gel, which is eluted with a mixture of 2% methanol and methylene chloride. The eluate is collected and mixed with a mixture of hydrochloric acid and ethanol, and the mixture is concentrated. The residue is crystallized from a mixture of ethyl acetate and ether and recrystallized from a mixture of methanol and ethyl acetate to give 345 mg of Compound (3) hydrochloride.

mp. 180.5°∼181°C (decomposition)

IR: νmaxNujol 2600 2300, 1649 cm-1.

To a solution of N,N'-thionyldiimidazole prepared from 2.95 g of imidazole and 1.29 g of thionyl chloride in 15 ml of dry methylene chloride is added 2.0 g of Compound (4), and the mixture is extracted with methylene chloride. The organic layer is washed with water, dried over Glauber's salt, and concentrated. The residue is chromatographed on a column of silica gel, which is eluted with methylene chloride to recover 750 mg of unreacted Compound (4). The eluate from 1% methanol-methylene chloride to 2% methanol-methylene chloride is collected and concentrated, and the resulting residue is crystallized from ethanolic hydrochloric acid and recrystallized from methanol-ethyl acetate-ether to give 310 mg of Compound (5).

mp. 153°-163°C

To a solution of 1 g of Compound (2) in 5 ml of dimethylformamide is added 322 mg of a 60% suspension of sodium hydride in mineral oil with ice-cooling, and the mixture is stirred for 5 minutes, mixed with 1.14 g of methyliodide, and stirred at room temperature for 10 minutes. The reaction mixture is diluted with ice water and extracted with ether. The organic layer is washed with water, dried over Glauber's salt, and concentrated. The residue is chromatographed on a column of silica gel and eluted with 37% methanol-methylene chloride. The eluate is concentrated, and the residue is crystallized from hydrochloric acid-ethanol and recrystallized from methanol-acetic acid to give 520 mg of Compound (6).

mp. 190°-195°C

Elemental Analysis (for C12 H12 ON2.HCl): Calcd(%): C, 60.89; H, 5.54; N, 11.84; Cl, 14.98; Found(%): C, 60.78; H, 5.52; N, 11.73; Cl, 15.02.

The following compounds are prepared in the same manner as mentioned in the above Examples.

__________________________________________________________________________
##STR13##
Ex. mp (°C.)
No.
m X Y R1 R2
R3
Salt or
__________________________________________________________________________
IR
4 O -- 2-O CH3 CH3
Im -- 164-165
5 " " "
##STR14## Ph Im " 155-156
6 " " " C2 H5
CH2 HCl . 1/2H2 O
159-162
7 " " " n-C3 H7
" " 146-148
8 " " " n-C4 H9
" -- oily product
ν film
1638
cm-1
9 " " " (CH2)3N(CH3)2
" 1/4CH3 OH
oily product
νfilm
1632
cm-1
10 " " " CH2 Ph " HCl 154-156
11 " " "
##STR15## " -- 85-86
12 " " " " " HCl 180.5-181
13 " " "
##STR16## " " 148.5-149
14 " " "
##STR17## " " 161-163
15 " " "
##STR18## " " 172-174
16 " " "
##STR19## " -- 94-94.5
17 " " "
##STR20## " HCl 180-183
18 " " "
##STR21## " " 138-147
19 " " "
##STR22## " -- oily product
νfilm
1639 cm-1
20 " " "
##STR23## " " oily product
νfilm
1630 cm-1
21 " " "
##STR24## " HCl 139-142
22 " " "
##STR25## " " 165-172
23 " " " (CH2)2 Ph
" (COOH)2
122.5-124.5
24 " " " (CH2)2N(C2 H5)2
" 2(COOH)2
80-81
25 " " " (CH2)2N(CH2 Ph)2
" -- oily product
νfilm
1634
cm-1
26 " " "
##STR26## " 2(COOH)2
153.5-155
27 " " " (CH2)2OPh
" HCl 158-160
28 " " "
##STR27## " " 140-142
29 " " " (CH2)3Ph
" -- oily product
νfilm
1639
cm-1
30 " " " (CH2)3N(CH3)2
" 2(COOH)2
125-127
31 " " " (CH2)3N(C2 H5)2
" " 146.5-147.5
32 " " "
##STR28## " -- oily product
νfilm
1635 cm-1
33 " " "
##STR29## " HCl 138-140
34 " " " CH3 CH ∼ CH3 *
-- oily product
νfilm
1660
cm-1
35 " " " CH2 Ph CH ∼ CH3 ***
" oily product
ν film
1659
cm-1
36 " " "
##STR30## CH ∼ CH3 *
HCl 175-177
37 " " "
##STR31## CH ∼ CH3 **
" 185-187
38 " " "
##STR32## CH ∼ CH3 ***
-- oily product
νfilm
1658 cm-1
39 " " "
##STR33## CH ∼ CH3 ***
HCl 156-158
40 " " " CH2 Ph C(CH3)2
-- oily product
νfilm
1665
cm-1
41 " " "
##STR34## " HCl 137-138
42 " " "
##STR35## " -- 62.5-64
43 " " "
##STR36## " " 100-102
44 " " "
##STR37## " " 100-101
45 " " "
##STR38## " " 58-60
46 " " " (CH2)2OPh
" " 76-78
47 " " "
##STR39## " " oily product
νfilm
1670 cm-1
48 1 4-Cl " CH3 CH2 HCl . 1/2H2 O
193-196
49 " " "
##STR40## " -- 132-133
50 " " " (CH2)3N(CH3)2
" 2(COOH)2
142-143.5
51 " 5-Cl "
##STR41## H Ph -- 115-116
52 " " " CH2 Ph Ph Im -- 166.5-167
53 " " "
##STR42## " " -- 187-188
54 " " "
##STR43## " " -- 189-191
55 " " "
##STR44## " " -- 165-167
56 " " "
##STR45## " " -- 172-173.5
57 " " " CH2 Ph CH2 HCl . 1/10H2 O
174-175
58 " " "
##STR46## " " 188-190
59 " " "
##STR47## " HCl . H2 O
172-174
60 " " "
##STR48## " HCl 165-172
61 " " " CH3 " " 239
62 " " " n-C3 H7
" " 178-181
63 " " " CH2 Ph CH ∼ CH3 ***
" 132-134
64 " " "
##STR49## " " 211-212
65 " " "
##STR50## " " 170-174
66 " " " CH2 Ph C(CH3)2
" 192-193.5
67 " " "
##STR51## " " 201-203
68 " " "
##STR52## " " 193-194
69 " " "
##STR53## " -- 106-108
70 " " "
##STR54## " 1/3H2 O
oily product
νfilm
1668 cm-1
71 " " " CH3 CH ∼ Ph
-- 118-118.5
72 " " " CH2 Ph CH ∼ C2 H5 ***
-- 158.5-159.5
73 " " "
##STR55## " HCl 220-222
74 " " "
##STR56## " HCl 166-167
75 " " " (CH2)3N(CH3)2
CH2 2(COOH)2
105.5-107
76 "
##STR57## "
##STR58## " HCl 193-195
77 2 3,5-Cl " CH2 Ph " " 170-172
78 " " "
##STR59## " " 155-165
79 " " "
##STR60## " " 170-171
80 " " "
##STR61## " " 150-153.5
81 " " "
##STR62## " 2(COOH)2 . 1/3H2
153-154
82 " " " (CH2)3N(CH3)2
" 2(COOH)2
119-120
83 0 -- 3-O
##STR63## " 1/2H2 O
oily product
νfilm :
1638 cm-1
84 " " 2-NH
" CH3
Im -- 143.5-144
85 " " " " CH2 " 147-148
86 " "
##STR64##
" " " 101-101.5
87 1 5-Cl 2-O (CH2)3N(CH3)2
C(CH3)2
2(COOH)2 . CH3
101-104
88
##STR65## "
##STR66## H H HCl 166-167
89
##STR67## " " " " -- 154-156
90
##STR68## " " " " " 142-143
91 " " " CH2 -- 120-121
__________________________________________________________________________
(Note)-
The meanings of abbreviations are as
Ph = phenyl
Im = imidazolyl
i-Pr = isopropyl
Tr = trifluoroacetyl
*means that methyl (ethyl, phenyl) group takes cisform to imidazolyl
group.
**means that methyl (ethyl, phenyl) group takes transform to imidazolyl
group.
***means the mixture of cis and transform.

Compound (2) (500 mg) is hydrogenated in 14% hydrochloric acid-methanol (5 ml) in the presence of platinum oxide in a hydrogen stream. After the absorption of 1 mole of hydrogen, the reaction is stopped. The reaction is filtered and the filtrate is concentrated. The residue is mixed with aqueous sodium hydrogencarbonate solution and extracted with methylene chloride. The organic layer is washed with water, dried over Glauber's salt and concentrated. The residue is crystallized from ethyl acetate-isopropyl ether to give Compound (7) (456 mg). mp. 170.5°∼172°C

To a solution of N,N'-thionyldiimidazole prepared from imidazole (4.12 g), thionyl chloride (1.8 g), and dry methylene chloride (20 ml) is added Compound (1) (2 g), and the mixture is allowed to stand at room temperature overnight. The reaction mixture is mixed with ice-water and extracted with methylene chloride. The organic layer is washed with water, dried, and concentrated. The residue is washed with ethyl acetate-ether to give Compound (9) (2.72 g).

mp. 183°∼193°C

Hydrochloride of Compound (9) (2HCl.H2 O)

mp. 124°∼127°C

The preparation for fungicides are as follows:

A mixture of Compound (3) hydrochloride prepared in Example 1 (5 weight parts), clay (85 weight parts), and talc (10 weight parts) is pulverized and formulated into a dust.

A mixture of a compound prepared in Example 8 (50 weight parts), diatomaceous earth (45 weight parts), and calcium alkylbenzenesulfonate (2.5 weight parts) is pulverized, admixed, and formulated into a wettable powder.

A mixture of the compound prepared in Example 27 (30 weight parts), xylene (60 weight parts), and polyoxyethylene alkyl aryl ether (10 weight parts) is admixed and formulated into an emulsion.

A mixture of the compound prepared in Example 3 (5 weight parts), clay (85 weight parts), and talc (10 weight parts) is pulverized and formulated into a dust.

A mixture of the compound prepared in Example 48 (50 weight parts), diatomaceous earth (45 weight parts), and calcium alkylbenzenesulfonate (2.5 weight parts) is pulverized, admixed, and formulated into a wettable powder.

A mixture of the compound prepared in Example 7 (30 weight parts), xylene (60 weight parts), and polyoxyethylene alkyl aryl ether (10 weight parts) is admixed and formulated into an emulsion.

The compound prepared in Example 62 (10 weight parts) is dissolved in water (90 weight parts) to give a solution.

The preparations for antimycotics are as follows:

______________________________________
Cream: The compound prepareed in Example 13
10 g
Bees wax 100 g
Cetyl alcohol 50 g
2-Octyldodecanol 50 g
Propylene glycol 300 g
Mixture (1:1 w/w) of sorbitan mono-
stearate and polyoxyethylene sorbitan
50 g
monostearate
Mixture (1.9:0.2 w/w) of butyl paraben
and methyl paraben 2 g
Mixture (0.06:1.25:9 w/w/w) of phosphoric
acid, sodium hydroxide and monosodium
10 g
phosphate dihydrate
Distilled water 428 g
1000 g
______________________________________
______________________________________
Gel: Nitrate of the compound prepared in
Example 13 10 g
Carbopol 940 (carboxyvinyl polymer)
15 g
Ethanol 100 g
Propylene glycol 650 g
Triisopropanolamine 10 g
Distilled water 215 g
1000 g
______________________________________

Takahashi, Toshio, Matsumoto, Hiroshi, Ogata, Masaru, Watanabe, Yoshihachi, Tawara, Katsuya

Patent Priority Assignee Title
4459412, Dec 05 1980 SHIONOGI & CO , LTD 1-Benzylimidazole derivatives
4584311, Jan 09 1984 Mitsui Toatsu Chemicals, Inc. Microbiocidal 1-[1-(alkoxyphenyl)vinyl]-1H-imidazoles
4755526, Jun 18 1984 Eli Lilly and Company Method of inhibiting aromatase
4780471, Jul 01 1986 Shionogi & Co., Ltd. Fungicidal azole derivatives
4894381, Jun 27 1987 Bayer Aktiengesellschaft Microbicidal (azolyl-vinyl)-phenol alkenyl ethers
5216007, Oct 01 1980 Rohm and Haas Company Substituted ethylene imidazole and triazoles
5256683, Dec 29 1988 Rhone-Poulenc Agrochimie Fungicidal compositions containing (benzylidene)-azolylmethylcycloalkane
5380743, Dec 29 1988 Rhone-Poulenc Agrochimie Fungicidal compositions containing (benzylidene)-azolymethylcycloalkane
5466704, Feb 16 1991 E. R. Squibb & Sons, Inc. N-substituted imidazole and benzimidazole derivatives useful as angiotenson II antagonists
5639918, Dec 29 1988 Rhone-Poulenc Agrochimie Intermediate compounds useful in the preparation of fungicidal compositions containing (benzylidene)-azolylmethyclycloalkane
5965743, Apr 27 1994 Nippon Soda Co., Ltd. N-substituted imidazol derivative
Patent Priority Assignee Title
3709901,
3985766,
4006243, Apr 11 1974 Schering Aktiengesellschaft Amino-, mercapto- and -oxy-substituted-phenyl and -phenalkyl imidazoles
4226878, Jun 13 1978 Kissei Pharmaceutical Co., Ltd.; ONO Pharmaceutical Co., Ltd. Imidazole derivative
//////
Executed onAssignorAssigneeConveyanceFrameReelDoc
Jun 06 1980Shionogi & Co., Ltd.(assignment on the face of the patent)
Nov 11 1981OGATA, MASARUSHIONOGI & CO , LTD ASSIGNMENT OF ASSIGNORS INTEREST 0039440679 pdf
Nov 11 1981TAWARA, KATSUYASHIONOGI & CO , LTD ASSIGNMENT OF ASSIGNORS INTEREST 0039440679 pdf
Nov 16 1981WATANABE, YOSHIHACHISHIONOGI & CO , LTD ASSIGNMENT OF ASSIGNORS INTEREST 0039440679 pdf
Nov 19 1981MATSUMOTO, HIROSHISHIONOGI & CO , LTD ASSIGNMENT OF ASSIGNORS INTEREST 0039440679 pdf
Nov 25 1981TAKAHASHI, TOSHIOSHIONOGI & CO , LTD ASSIGNMENT OF ASSIGNORS INTEREST 0039440679 pdf
Date Maintenance Fee Events


Date Maintenance Schedule
May 04 19854 years fee payment window open
Nov 04 19856 months grace period start (w surcharge)
May 04 1986patent expiry (for year 4)
May 04 19882 years to revive unintentionally abandoned end. (for year 4)
May 04 19898 years fee payment window open
Nov 04 19896 months grace period start (w surcharge)
May 04 1990patent expiry (for year 8)
May 04 19922 years to revive unintentionally abandoned end. (for year 8)
May 04 199312 years fee payment window open
Nov 04 19936 months grace period start (w surcharge)
May 04 1994patent expiry (for year 12)
May 04 19962 years to revive unintentionally abandoned end. (for year 12)